pharmaceuticals

Female patient on gurney

How AbbVie Won Big on Earnings

AbbVie Inc. (NYSE: ABBV) released its second-quarter earnings report before the markets opened on Friday. The company said that it had $1.26 in earnings per share (EPS) on $6.45 billion ...
Read Full Story »
coins

Bristol-Myers Earnings Don’t Appear to Be Enough for Investors

Bristol-Myers Squibb Co. (NYSE: BMY) released its second-quarter earnings report before the markets opened on Thursday. The company posted $0.69 in earnings per share (EPS) on $4.87 billion in revenue, ...
Read Full Story »
Prescription drugs

Short Sellers Get Selective on Major Pharma

The short interest data have been released for the July 15 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
Test tubes

JPMorgan Bullish on Biotech: 3 Top Picks to Buy Now

We have noted recently that large pharmaceuticals and biotech have been hammered, and now may be offering outstanding total return potential. While the larger pharmaceutical stocks have done better recently, the ...
Read Full Story »
Medicine pills

Why Eli Lilly Earnings Are So Dynamic

Eli Lilly and Co. (NYSE: LLY) released its second-quarter earnings report before the markets opened on Tuesday. Currently this company is in the middle of a very dynamic product launch, ...
Read Full Story »
Medicine pills

Top Analyst Thinks Big Pharmaceutical Stocks Will Outperform the Rest of 2016

Ever since the Hillary Clinton high drug price tweet in September of last year, the major pharmaceuticals and biotechs have struggled, and while performance has improved over the past quarter, ...
Read Full Story »
M&A

Why the Relypsa Merger Is a Great Idea

Relypsa Inc. (NASDAQ: RLYP) made a splash in the markets on Thursday after the company announced an acquisition agreement. Although the biotech and pharma industries have been hit hard in ...
Read Full Story »
Female patient on gurney

Could This Be the Turning Point for Progenics and Valeant?

Shares of Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) and Valeant Pharmaceuticals International Inc. (NYSE: VRX) made handy gains in the market on Wednesday following a key U.S. Food and Drug Administration (FDA) ...
Read Full Story »
biotech word cloud

4 Speculative Biotech and Biohealth Analysts Calls for Huge Upside

The week of July 15 may have ended on a soft note, but the week was more importantly a one that brought new highs in the Dow Jones Industrial Average and ...
Read Full Story »
Female patient on gurney

Synergy Pharmaceuticals Sinks on FDA Update

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) stumbled on Friday, and over the course of the week for that matter, despite a strong upward push in the broad markets. The company has ...
Read Full Story »
Medicine pills

Pharmaceutical Stocks May Be the Best Total Return Play: 3 to Buy Now

If one sector has struggled this year it has been the health care sector, which is surprising given that usually it is considered to be very defensive. But ever since a ...
Read Full Story »
Pills and tablets

Why the Teva Acquisition Proves It Is a Stock to Own for the Decade

It is no secret that drug price pressure and the winds of political change have been hurting almost every large company tied to the pharmaceutical and biotech industries. Even though ...
Read Full Story »
Prescription drugs

Short Sellers Run for Cover From Major Pharma

The short interest data have been released for the June 30 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
blue eye

Shire Gains Key FDA Approval in Dry Eye Treatment

Shire PLC (NASDAQ: SHPG) made waves Tuesday morning following a key U.S. Food and Drug Administration (FDA) approval. The company announced that the FDA has approved Xiidra (lifitegrast ophthalmic solution) 5%, ...
Read Full Story »
Doctor, Health (pulse) copy

Protagonist Therapeutics Files for IPO

Protagonist Therapeutics has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were listed in the filing, but the offering ...
Read Full Story »